Mature Response Data from A Phase 2 study of PI3K-Delta Inhibitor Idelalisib in patients with Double (Rituximab and Alkylating agent)-Refractory indolent B-cell Non-Hodgkin Lymphoma (iNHL)

Authors
Publication date
1 December 2013
Publisher

Abstract

Abstract is not available.

    Similar works

    Full text

    thumbnail-image

    Available Versions

    The University of Manchester - Institutional Repository

    redirect
    oaioai:pure.atira.dk:publications...
    Last time updated on 01/02/2017